Assessing antidepressant activity in rodents: Recent developments and future needs

Trends in Pharmacological Sciences

Volumn 23, Issue 5, 2002, Pages 238-245

  Cryan, John F ^a   Markou, Athina ^b   Lucki, Irwin ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR;

ANHEDONIA; DEPRESSION; DISEASE MODEL; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; FORCED SWIMMING TEST; GENETICS; HYPOTHESIS; IDIOPATHIC DISEASE; LEARNED HELPLESSNESS; MOUSE STRAIN; NERVOUS SYSTEM; NEUROPATHOLOGY; NONHUMAN; OLFACTORY BULBECTOMY; PREDICTION; PRIORITY JOURNAL; RELIABILITY; REVIEW; REWARD; RODENT; STRAIN DIFFERENCE; STRESS; WITHDRAWAL REFLEX;

ANIMALS; ANTIDEPRESSIVE AGENTS; MICE; MODELS, ANIMAL; OLFACTORY BULB; RATS; SPECIES SPECIFICITY; SUBSTANCE WITHDRAWAL SYNDROME; SWIMMING;

EID: 0036570222     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)02017-5     Document Type: Review

References (62)

1. Research and treatment approaches to depression
2. Animal model of depression. I. Review of evidence: Implications for research
3. Animal models of psychiatric disorders
4. Animal models of depression: An overview
5. Depression: A new animal model sensitive to antidepressant treatments
6. Animal models of depression: Utility for transgenic research
7. Is the forced swimming test a suitable model for revealing antidepressant activity?
8. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs
9. (2C) receptors
10. Noradrenergic lesions differentially alter the antidepressant-like effect of reboxetine in a modified forced swim test
11. Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression
12. Antidepressant-like actions of pregnancy, and progesterone in Wistar rats forced to swim
13. Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test
14. Prefrontocortical dopamine depletion induces antidepressant-like effects in rats and alters the profile of desipramine during Porsolt's test
15. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats
16. The olfactory bulbectomized rat as a model of depression: An update
17. Combining pindolol and paroxetine in an animal model of chronic antidepressant action - can early onset of action be detected?
18. Changes in defensive behaviors following olfactory bulbectomy in male and female rats
19. Role of aversively motivated behavior in the olfactory bulbectomy syndrome
20. Antidepressants preferentially enhance habituation to novelty in the olfactory bulbectomized rat
21. Serotonergic hyperinnervation of the frontal cortex in an animal model of depression, the bulbectomized rat
22. Stressor-induced alterations in serotonergic activity in an animal model of depression
23. Striatal glutamate release during novelty exposure-induced hyperactivity in olfactory bulbectomized rats
24. Effects of sertraline on regional neuropeptide concentrations in olfactory bulbectomized rats
25. Effects of olfactory bulbectomy on neuropeptide gene expression in the rat olfactory/limbic system
26. An in-vivo magnetic resonance imaging study of the olfactory bulbectomized rat model of depression
27. Modeling geriatric depression in animals: Biochemical and behavioral effects of olfactory bulbectomy in young versus aged rats
28. Animal models of depression and schizophrenia
29. Animal models for the study of antidepressant activity
30. Chronic mild stress and depressive disorder: A useful new model?
31. Learned helplessness in the rat: Improvements in validity and reliability
32. Amphetamine withdrawal: A behavioral evaluation
33. Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement
34. Effects of withdrawal from an escalating dose schedule of d-amphetamine on sexual behavior in the male rat
35. Postcocaine anhedonia. An animal model of cocaine withdrawal
36. Post-amphetamine depression of self-stimulation responding from the substantia nigra: Reversal by tricyclic antidepressants
37. Euphorigenic drugs: Effects on the reward pathways of the brain
38. Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats
39. Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats
40. Repeated electroconvulsive shock attenuates the depressive-like effects of D-amphetamine withdrawal on brain reward function in rats
41. What's Wrong With My Mouse?
42. Sensitivity to the effects of pharmacologically selective antidepressants indifferent strains of mice
43. Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice
44. Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test
45. Are Wistar-Kyoto rats a genetic animal model of depression resistant to antidepressants?
46. Brain-derived-neurotrophic-factor (BDNF) stress response in rats bred for learned helplessness
47. A genetic mouse model of helplessness sensitive to imipramine
48. Elucidation of the neurobiology of depression: Insights from a novel genetic animal model
49. 1A receptor-mediated responses: Application to emotion and receptor action
50. A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse
51. Humanization of mouse 5-hydroxytryptamine1B receptor gene by homologous recombination: In vitro and in vivo characterization
52. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs
53. The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat
54. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist
55. Metyrapone displays antidepressant-like properties in preclinical paradigms
56. Antidepressant-like actions of an AMPA receptor potentiator (LY392098)
57. Limitations on the use of the C57BL/6 mouse in the tail suspension test
58. Behavioral despair in mice after prenatal stress
59. High corticosterone levels in prenatally stressed rats predict persistent paradoxical sleep alterations
60. Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation
61. 1A receptor antagonist, WAY-100635